Clinical Trial Update: Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults [Phase 1]

View source ↗

Summary

This Phase 1 open-label study evaluated the safety, tolerability, pharmacokinetics, and virologic effects of two HIV broadly neutralizing antibodies, VRC01LS an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC01LS (VRC01LS)
• VRC07-523LS

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1 | Phase 1 | Status: COMPLETED | Results posted: 2021-02-23